I think management will lower Recothrom's price to match bovine thrombin if sales doesn't pick up. I guess the good thing about ZGEN is they got atacicept and lambda in their pipeline to keep investors hopes alive. I hope ZGEN won't dissapoint me on interferon lambda data.